Corcept Therapeutics, Inc. (CORT)
111.62
-1.18
(-1.05%)
USD |
NASDAQ |
Sep 04, 16:00
111.62
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics SG&A Expense (TTM) : 556.47M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 556.47M |
| March 31, 2026 | 503.42M |
| December 31, 2025 | 448.72M |
| September 30, 2025 | 401.86M |
| June 30, 2025 | 351.63M |
| March 31, 2025 | 314.71M |
| December 31, 2024 | 280.32M |
| September 30, 2024 | 244.10M |
| June 30, 2024 | 215.62M |
| March 31, 2024 | 191.96M |
| December 31, 2023 | 184.26M |
| September 30, 2023 | 179.43M |
| June 30, 2023 | 169.33M |
| March 31, 2023 | 163.86M |
| December 31, 2022 | 152.85M |
| September 30, 2022 | 142.81M |
| June 30, 2022 | 138.18M |
| March 31, 2022 | 130.40M |
| December 31, 2021 | 122.36M |
| September 30, 2021 | 115.77M |
| June 30, 2021 | 111.76M |
| March 31, 2021 | 107.30M |
| December 31, 2020 | 105.33M |
| September 30, 2020 | 106.76M |
| June 30, 2020 | 104.48M |
| Date | Value |
|---|---|
| March 31, 2020 | 103.50M |
| December 31, 2019 | 100.36M |
| September 30, 2019 | 94.78M |
| June 30, 2019 | 91.85M |
| March 31, 2019 | 87.24M |
| December 31, 2018 | 81.29M |
| September 30, 2018 | 76.52M |
| June 30, 2018 | 71.69M |
| March 31, 2018 | 65.82M |
| December 31, 2017 | 62.42M |
| September 30, 2017 | 57.38M |
| June 30, 2017 | 51.84M |
| March 31, 2017 | 49.85M |
| December 31, 2016 | 45.24M |
| September 30, 2016 | 33.48M |
| June 30, 2016 | 31.84M |
| March 31, 2016 | 29.06M |
| December 31, 2015 | 28.09M |
| September 30, 2015 | 36.13M |
| June 30, 2015 | 35.94M |
| March 31, 2015 | 34.56M |
| December 31, 2014 | 34.92M |
| September 30, 2014 | 34.39M |
| June 30, 2014 | 32.47M |
| March 31, 2014 | 32.66M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Liquidia Corp. | 192.66M |
| Eli Lilly & Co. | 12.24B |
| Indivior Pharmaceuticals, Inc. | 591.00M |
| Crinetics Pharmaceuticals, Inc. | 214.37M |
| Merck & Co., Inc. | 11.14B |